Skip to Main Content

The pitches always sounded promising: A new software app could track glucose levels for people with diabetes or soothe the brains of insomniacs. Most pharma executives would politely smile and nod, but then park their money somewhere else.

Not anymore.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED